NDA group is pleased to announce the expansion of its NDA Advisory Board with the appointment of Chantal van Gils, MD, Ph.D., a seasoned specialist in epidemiological analyses and outcome research.

Chantal's expertise in integrated evidence planning is critical to inform today’s development and regulatory decision-making along the value chain and product life cycles.  A medical doctor by training, with extensive experience in oncology, Chantal holds a Ph.D. in Health Economics and MSc in Clinical Epidemiology from the Erasmus University in Rotterdam.  She has authored many articles and published her research in peer-reviewed journals the past two decades

Chantal joins NDA from IQVIA where she held the position as global Director of Epidemiology.  She has led global evidence generation, market access projects and real-world evidence studies for innovative medicine projects. Chantal brings a wealth of professional experience in harnessing population-specific analyses and quantitative methods to inform both interventional and observational clinical studies including pragmatic trials, natural history of diseases, registry-based data, patient-related outcome reports or multi-dimensional molecular medicine data. In her role as NDA Advisory Board Director of Epidemiology & RWE, she will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy or other health authority interactions for high priority programs and/or non-interventional studies across all therapeutics areas, and notably oncology and ATMP.

Kurt Stoeckli, President of NDA Advisory Board, comments:

“I am excited to have Chantal join the NDA Advisory board. Innovative therapies have become more tailor-made, following emerging paradigms of precision medicine. Benefit / risk assessment is done in eligible subpopulations of patients, the one-size-fits-all model is no longer the rationale for many innovative assets. Decision-making by innovators and by regulators is supported by a variety of data from various sources and of increasing volumes and complexity.  Understanding how to harness such data in a consistent and strategic way, and in support of relevant decision-making has become a decisive factor in terms of speed, costs, and risk mitigation.  It is all about understanding which patients will benefit most from the proposed innovation, and to assess its value. Chantal brings profound knowledge in this emerging area, combined with practical experience and contextual judgement. She will be able to help clients to come-up with the best global strategy, so as to get innovative medicines the fastest and safest way to the patients in need,” finishes Stoeckli.

Chantal is looking forward to stepping into her new role and says:

“I am very pleased to join the NDA team. With the trend towards precision medicine, regulators have discovered the value of ‘real-world’ data to supplement clinical research for benefit/risk assessment. As epidemiologist with extensive experience in all kinds of real-world research, I am very excited about this trend and even more about the opportunity to be part of the NDA team working together with NDA colleagues to support clients to develop tailor-made evidence strategies to meet challenging regulatory requirements.” 

Johan Strömquist, CEO of NDA Group, commented on the appointment:

“The NDA Advisory Board is one of a kind – no other professional body comes as close to reflecting the current opinions and practices of the world’s regulatory and reimbursement agencies. I am delighted to welcome Chantal to our team. I very much look forward to working with her to help bring more good medicines to people all over the world.”



Dr Chantal van Gils

NDA Advisory Board Director

Read more

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.